National Institute of Toxicological Research, Korea Food and Drug Administration

Alpha-hydroxy acids (AHAs) are used in cosmetic products as pH adjuster, mild exfoliant and humectant-skin conditioner. Cosmetics containing high concentration and low pH of AHAs can cause side effects such as epidermal crusing and necrosis, whereas low dose of AHA induces thickness of stratum corneum. In this study, we examined histopathological effect of glycolic acid on guinea pig skin. We also compared with the effects of phorbol 12-myristate 13-acetate (TPA) and UVB irradiation. Different doses of glycolic acid (10 to 70%, pH 3.0), TPA (0.1 mM) and UVB irradiation (0.4 and 3 J/am) were treated on back skin of guinea pig for 14 days. Histological changes were examined with hematoxylin-eosin staining method. The epidermis got thicker in glycolic acid-treated skin compared with control. More than 50% of glycolic acid caused disruption of normal skin structure. The thickness of epidermis in UVB-irradiated skin also increased, but that in TPA treated-skin did not. Glycolic acid induced hyperplasia in epidermis (keratinocytes) at 10% to 70%, and induced necrosis of the cells in epidermis at more than 30%. Glycolic acid induced hyperplasia and necrosis of cells in dermis (fibroblast) at 50% and 70%. TPA induced necrosis of the cells in epidermis and dermis and infiltration of inflammatory cells (lympocytes and eosinophilic cells). The number of apoptotic cells was increased by glycolic acid and UVB treatment. These results show that the examined chemicals and UVB irradiation caused differential skin responses.

[PA4-9] [04/21/2000 (Fri) 10:30 - 11:30 / [1st Fl, Bldg 3]]

Study of DK-35C, a carbapenem antibiotics, in forward gene mutation assay in L5178Y mouse lymphoma cells and in vivo cytogenetic assay

Kim JR^{o1}, Kim YJ¹, Kwon OS¹, Kim MK², Nam KH², Ryu JC¹

¹Toxicology Laboratory, Korea Institute of Science and Technology, ²Dong-Kook Pharmaceutical Company

To investigate the toxicity of a carbapenem antibiotics DK-35C, we performed the forward gene mutation assay in L5178Y mouse lymphoma cells and *in vivo* supravital cytogenetic assay in mice. In forward gene mutation assay with L5178Y mouse lymphoma cell, DK-35C revealed statistically significant increase in mutation frequency (MF) at the highest dose (1250 \(mu/ml)\) in the absence of metabolic activation system. However, no significant increase of MF was observed in the presence of S-9 metabolic activation system at concentrations (625~5000 \(mu/ml)\) used. In supravital staining micronucleus assay with mouse peripheral reticulocytes, no significant increase of micronucleated reticulocytes(MNRETs) was observed after intraperitoneal administration of DK-35C (463.3, 231.7, and 115.9 \(mu/ml)\) to mice. From the results that chromosomal aberration previously reported and MNRETs in mouse reticulocytes were not induced by DK-35C, this data indicate that DK-35C itself may induce some point mutation at the high concentration.

[PA4-10] [04/21/2000 (Fri) 10:30 - 11:30 / [1st Fl, Bldg 3]]

Metabolic Phenotyping and Genotype of Dextromethorphan

Yang WK*, Chung HS, Choi HK, Jin WT, Yang YG, Roh HK and Yoo YC

National Institute of Scientific Investigation, Seoul, *Inha University, Incheon, Korea

The abuse of dextromethorphan has been prevalent for longer than 10 years in Korea and its fatal cases were reported even though it has proved to be very safe. In this study, to investigate the safety and tolerance assesment of dextromethorphan, the metabolic phenotyping and genotype of dextromethorphan were studied.

After a single 30mg dextromethorphan oral administration to 60 volunteers, dextromethorphan and its metabolites, dextrorphan, hydroxymorphinan and methoxymorphinan concentrations were measured

in urine collected during 8 hrs after the drug administration.

CYP2D6 phenotype was determined from the ratio of dextromethorphan to dextrorphan. GC/MS was used to quantify dextromethorphan and its metabolites. For genotyping, mutant alleles of the CYP2D6 gene were identified.

Twenty-two subgects(37%) were homozygous for CYP2D6*10B, 22 subjects (37%) were heterozygous for this allele, while in 16 subjects(26%) no exone 1 mutation could be found. The frequency of CYP2D6*10B -allele containing the C188 →mutation was 55% of total subjects studied. Animal study showed the level of excreted dextrorphan was higher in female than male, incurring sex differences.

[PA4-11] [04/21/2000 (Fri) 10:30 - 11:30 / [1st Fl, Bldg 3]]

The protective effects of propolis on hepatic injury and its mechanism

Seo KW, Park M, Kim KB, Song YJ, Yoon KR, Kim BY

Toxicol. Dept., KFDA, *Dept. Food Sci. & Technol., Chung Ang Univ.

Propolis (PP) is known to have several biological properties such as anticancer, antioxidative, antiinflammatory and antibiotic activities. The purpose of this study is to investigate the protective effects of PP on hepatotoxicity induced by acetaminophen (AA), and the mechanism of its hepatoprotective effect. In rat hepatocyte culture, pretreatment with PP (0.001, 0.01, 0.1, 0.2 and 0.4 mg/ml, 24 hrs) significantly decreased the cytotoxicity by AA (0.5 mM) in a dose-dependent manner. In mice, pretreatment with PP (10 and 25 mg/kg, p.o., 7 days) also decreased the mortality and the incidence and severity of hepatic necrosis induced by AA (400 mg/kg, i.p.). After treatment with PP for 7 days, the hepatic enzyme activities of cytochrome P450 monooxygenases (P450s), UDP-glucuronyltransferase, phenoisulfotransferase (PST), glutathione S-transferase (GST) were measured in both rats and mice. In rats, PP (50 and 100 mg/kg, p.o.) decreased the activities of P4502E1, but significantly increased the activities of GST and PST. In contrast, the activities of P4501A2, 2B1, 3A4 and 2E1 were dramatically inhibited, and activity of PST was significantly enhanced in mice treated with PP (10 and 25 mg/kg, p.o.). However PP had no effect on the activities of antioxidant enzymes in two species. These results suggest that PP has protective effect on hepatic injury, and that its effect may be explained by inhibition on phase I enzymes and induction of phase II enzymes.

[PA4-12] [04/21/2000 (Fri) 10:30 - 11:30 / [1st Fl, Bldg 3]]

Developmental and Neurobehavioral Effects of Mycotoxin Fumonisin B1 in rats

Kwon OSO, JC Ryu

Toxicology Lab., Bioanalysis & Biotransformation Research Center, Korea Institute of Science and Technology, Seoul, Korea 136-791

The objective of this experiment is to investigate neurobehavioral and developmental effects of fumonisin B1 (FB1) after prenatal FB1 administration in rats. FB1 (0.8 or 1.6 mg/kg) was orally exposed to pregnant rats during gestational days 13 to 20, and aqueous solution was administered to control group. Maternal and offspring body weights, physical landmarks of incisor eruption, eye opening, testes descending and vaginal opening, open field activity, running wheel activity, and complex maze performance were included as endpoints for developmental and neurobehavioral measurement. Maternal body weights were not significantly altered after FB1 exposure. Percentage of maternal weight gain difference between control and 1.6 mg/kg FB1 groups was about 4%. Preand post-weaning weight of offspring after prenatal exposure to FB1 was not significantly changed, suggesting that FB1 of 0.8 or 1.6 mg/kg doses did not cross the placenta. Significant gender difference in running wheel activity on postnatal days 57 to 63 and complex maze performance on postnatal days 75 to 78 was observed.